Idelalisib in indolent NHL - has it finally found its niche?
Leuk Lymphoma
.
2021 May;62(5):1029-1030.
doi: 10.1080/10428194.2020.1836369.
Epub 2020 Oct 19.
Authors
Aswin Sekar
1
,
Matthew S Davids
1
Affiliation
1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
PMID:
33076732
DOI:
10.1080/10428194.2020.1836369
No abstract available
Publication types
Comment
MeSH terms
Follow-Up Studies
Humans
Lymphoma, Non-Hodgkin*
Purines
Quinazolinones* / adverse effects
Substances
Purines
Quinazolinones
idelalisib